Phreesia, Inc. (PHR) stock
Close on Nov 13, 2026Market cap $787.68MP/E 74.6Yield –
Earnings
Phreesia's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Phreesia's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2027ended Oct 31, 2026 | Dec 7, 2026Expected | – | – | – | – |
| Q2 FY2027ended Jul 31, 2026 | Sep 2, 2026during market hours | $129.50M | +10.4% | $0.03 | Release |
| Q1 FY2027ended Apr 30, 2026 | May 27, 2026during market hours | $130.90M | +12.9% | $0.05 | Release |
| Q4 FY2026ended Jan 31, 2026 | Mar 30, 2026during market hours | $127.10M | +15.9% | – | Release |
| Q3 FY2026ended Oct 31, 2025 | Dec 8, 2025during market hours | $120.30M | +12.6% | $0.07 | Release |
| Q2 FY2026ended Jul 31, 2025 | Sep 4, 2025during market hours | $117.30M | +14.9% | $0.01 | Release |
| Q1 FY2026ended Apr 30, 2025 | May 28, 2025before the open | $115.90M | +14.5% | – | Release |
| Q4 FY2025ended Jan 31, 2025 | Mar 12, 2025during market hours | $109.70M | +15.5% | -$0.11 | Release |
| Q3 FY2025ended Oct 31, 2024 | Dec 9, 2024during market hours | $106.80M | +16.6% | – | Release |
| Q2 FY2025ended Jul 31, 2024 | Sep 4, 2024during market hours | $102.10M | +19.0% | -$0.31 | Release |
| Q1 FY2025ended Apr 30, 2024 | May 30, 2024during market hours | $101.20M | +20.8% | -$0.35 | Release |
| Q4 FY2024ended Jan 31, 2024 | Mar 14, 2024during market hours | $95.00M | +24.0% | -$0.56 | Release |
| Q3 FY2024ended Oct 31, 2023 | Dec 5, 2023during market hours | $91.60M | +25.3% | -$0.58 | Release |
| Q2 FY2024ended Jul 31, 2023 | Sep 6, 2023during market hours | $85.80M | +26.4% | -$0.68 | Release |
| Q1 FY2024ended Apr 30, 2023 | May 31, 2023during market hours | $83.80M | +32.2% | -$0.70 | Release |
| Q4 FY2023ended Jan 31, 2023 | Mar 22, 2023during market hours | $76.60M | +32.1% | -$0.72 | Release |
| Q3 FY2023ended Oct 31, 2022 | Dec 8, 2022during market hours | $73.10M | +30.8% | -$0.76 | Release |
| Q2 FY2023ended Jul 31, 2022 | Sep 7, 2022during market hours | $67.90M | – | -$0.89 | Release |
| Q1 FY2023ended Apr 30, 2022 | Jun 2, 2022during market hours | $63.40M | – | -$0.99 | Release |
| Q4 FY2022ended Jan 31, 2022 | Mar 30, 2022during market hours | $58.00M | – | -$0.90 | Release |
| Q3 FY2022ended Oct 31, 2021 | Dec 8, 2021during market hours | $55.90M | – | -$0.71 | Release |
| Q2 FY2022ended Jul 31, 2021 | Sep 1, 2021during market hours | – | – | – | Filing |
| Q1 FY2022ended Apr 30, 2021 | Jun 3, 2021during market hours | – | – | – | Filing |
| Q4 FY2021ended Jan 31, 2021 | Mar 30, 2021during market hours | – | – | – | Filing |
| Q3 FY2021ended Oct 31, 2020 | Dec 8, 2020during market hours | – | – | – | Filing |
| Q2 FY2021ended Jul 31, 2020 | Sep 8, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Phreesia's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenue | FY2027 | $510.00M – $520.00M | $510.00M – $520.00M | Reaffirmed | Sep 2, 2026 |
| Adjusted EBITDAnon-GAAP | FY2027 | $125.00M – $135.00M | $125.00M – $135.00M | Reaffirmed | Sep 2, 2026 |
Guidance vs results
The last range Phreesia gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2026 | Revenue | $479.00M – $481.00M | $480.60MΣ4Q | Within range |
| FY2025 | Revenue | $418.00M – $420.00M | $419.80MΣ4Q | Within range |
Guidance history
Every forecast Phreesia put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Sep 2, 2026 | Adjusted EBITDA | FY2027 | $125.00M – $135.00M | Reaffirmed |
| Sep 2, 2026 | revenue | FY2027 | $510.00M – $520.00M | Reaffirmed |
| May 27, 2026 | Adjusted EBITDA | FY2027 | $125.00M – $135.00M | Reaffirmed |
| May 27, 2026 | revenue | FY2027 | $510.00M – $520.00M | Reaffirmed |
| Mar 30, 2026 | Adjusted EBITDA | FY2027 | $125.00M – $135.00M | Reaffirmed |
| Mar 30, 2026 | revenue | FY2027 | $510.00M – $520.00M | Lowered |
| Dec 8, 2025 | Adjusted EBITDA | FY2026 | $99.00M – $101.00M | Raised |
| Dec 8, 2025 | Adjusted EBITDA | FY2027 | $125.00M – $135.00M | New |
| Dec 8, 2025 | AHSCs | FY2026 | 4515 | Raised |
| Dec 8, 2025 | revenue outlook | FY2026 | $479.00M – $481.00M | Narrowed |
| Dec 8, 2025 | revenue | FY2027 | $545.00M – $559.00M | New |
| Sep 4, 2025 | Adjusted EBITDA | FY2026 | $87.00M – $92.00M | Raised |
| Sep 4, 2025 | AHSCs | FY2026 | 4500 | Reaffirmed |
| Sep 4, 2025 | revenue | FY2026 | $472.00M – $482.00M | Reaffirmed |
| May 28, 2025 | Adjusted EBITDA | FY2026 | $85.00M – $90.00M | Raised |
| May 28, 2025 | AHSCs | FY2026 | 4500 | Reaffirmed |
| May 28, 2025 | revenue | FY2026 | $472.00M – $482.00M | Reaffirmed |
| Mar 12, 2025 | Adjusted EBITDA | FY2026 | $78.00M – $88.00M | Reaffirmed |
| Mar 12, 2025 | AHSCs | FY2026 | 4500 | Reaffirmed |
| Mar 12, 2025 | revenue | FY2026 | $472.00M – $482.00M | Reaffirmed |
| Dec 9, 2024 | Adjusted EBITDA outlook | FY2025 | $34.00M – $36.00M | New |
| Dec 9, 2024 | Adjusted EBITDA outlook | FY2026 | $78.00M – $88.00M | New |
| Dec 9, 2024 | AHSCs | FY2025 | 4200 | New |
| Dec 9, 2024 | AHSCs | FY2026 | 4500 | New |
| Dec 9, 2024 | revenue outlook | FY2025 | $418.00M – $420.00M | New |
| Dec 9, 2024 | revenue outlook | FY2026 | $472.00M – $482.00M | New |
| Sep 4, 2024 | Adjusted EBITDA | FY2025 | $26.00M – $31.00M | Raised |
| Sep 4, 2024 | AHSCs | FY2025 | 4200 | New |
| Sep 4, 2024 | AHSCs | FY2026 | 4500 | New |
| Sep 4, 2024 | revenue outlook | FY2025 | $416.00M – $426.00M | Lowered |
| May 30, 2024 | Adjusted EBITDA | FY2025 | $21.00M – $26.00M | Raised |
| May 30, 2024 | revenue outlook | FY2025 | $416.00M – $426.00M | Lowered |
| Mar 14, 2024 | Adjusted EBITDA outlook | FY2025 | $12.00M – $20.00M | Raised |
| Mar 14, 2024 | revenue outlook | FY2025 | $424.00M – $434.00M | New |
| Dec 5, 2023 | Adjusted EBITDA | FY2024 | -$39.00M | Raised |
| Dec 5, 2023 | Adjusted EBITDA | FY2025 | $10.00M – $20.00M | New |
| Dec 5, 2023 | revenue | FY2024 | $353.00M – $356.00M | Reaffirmed |
| Dec 5, 2023 | revenue | FY2025 | $424.00M – $434.00M | New |
| Sep 6, 2023 | Adjusted EBITDA outlook | FY2024 | -$54.00M – -$49.00M | Raised |
| Sep 6, 2023 | revenue outlook | FY2024 | $353.00M – $356.00M | Reaffirmed |
| May 31, 2023 | Adjusted EBITDA | FY2024 | -$60.00M – -$55.00M | Raised |
| May 31, 2023 | revenue | FY2024 | $353.00M – $356.00M | New |
| Mar 22, 2023 | Adjusted EBITDA | FY2024 | -$65.00M – -$60.00M | New |
| Mar 22, 2023 | revenue | FY2024 | $353.00M – $356.00M | New |
| Dec 8, 2022 | Adjusted EBITDA outlook | FY2023 | -$95.00M | Raised |
| Dec 8, 2022 | average healthcare services clients | Q4 FY2023 | 150 | New |
| Dec 8, 2022 | cash and cash equivalents balance | Q4 FY2023 | $170.00M | New |
| Dec 8, 2022 | revenue outlook | FY2023 | $278.00M | Raised |
| Dec 8, 2022 | revenue target | FY2025 | $500.00M | New |
| Sep 7, 2022 | Adjusted EBITDA | FY2023 | -$109.00M – -$106.00M | Raised |
| Sep 7, 2022 | revenue | FY2023 | $273.00M – $275.00M | Raised |
| Jun 2, 2022 | Adjusted EBITDA outlook | FY2023 | -$126.00M – -$122.00M | Raised |
| Jun 2, 2022 | revenue outlook | FY2023 | $271.00M – $275.00M | New |
| Mar 30, 2022 | Adjusted EBITDA | FY2023 | -$154.00M – -$149.00M | New |
| Mar 30, 2022 | revenue | FY2023 | $271.00M – $275.00M | New |
| Dec 8, 2021 | Adjusted EBITDA | FY2022 | -$64.00M | New |
| Dec 8, 2021 | revenue | FY2022 | $211.00M | New |
| Dec 8, 2021 | revenue | FY2023 | +20% – +25% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Phreesia filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?